Eribulin + Doxorubicin + Cyclophosphamide + Pegfilgrastim
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Neoplasms
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast
Trial Timeline
Nov 1, 2011 → Jun 1, 2015
NCT ID
NCT01498588About Eribulin + Doxorubicin + Cyclophosphamide + Pegfilgrastim
Eribulin + Doxorubicin + Cyclophosphamide + Pegfilgrastim is a phase 2 stage product being developed by Eisai for Breast Neoplasms. The current trial status is terminated. This product is registered under clinical trial identifier NCT01498588. Target conditions include Breast Neoplasms, Breast Cancer, Breast Tumors.
What happened to similar drugs?
20 of 20 similar drugs in Breast Neoplasms were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01498588 | Phase 2 | Terminated |
Competing Products
20 competing products in Breast Neoplasms